If Kymriah is approved by the US FDA and the EMA, it will be the first time a chimeric antigen receptor T cell (CAR-T) therapy has been made available for two distinct indications in non-Hodgkin lymphoma and B-cell
If approved, Kymriah would represent the first chimeric antigen receptor T cell (CAR-T) therapy available for two distinct indications in non-Hodgkin lymphoma and B-cell
Although CLL is the most common leukemia affecting adults in Western countries, (2) according to a recent study, CLL/SLL is the second most frequent B-cell
malignancy, accounting for 18.
Diffuse large B-cell
lymphoma (DLBCL) is the most common lymphoid malignancy among adults and constitutes approximately 40% of non-Hodgkin lymphomas.
A major strength of GlobalData's epidemiological analysis is the exclusive use of country-specific sources, allowing for a meaningful comparison of the epidemiological characteristics of B-cell
NHL in the 7MM.
The discovery could lead to the development of an early-warning test that identifies patients at high risk of developing B-cell
lymphomas, enabling proactive treatment to prevent tumours from growing.
According to the company's PIXUVRI's market access in Italy for multiply relapsed or refractory aggressive B-cell
NHL is based on the results of the EXTEND, or PIX301, pivotal randomized Phase 3 clinical trial.
Primary cutaneous diffuse large B-cell
lymphoma, leg type must be differentiated from anaplastic large-cell lymphoma and non-lymphoid tumors such as cutaneous metastases.
Three of the five responses were in patients with diffuse large B-cell
burgdorferi infections can cause reactive B-cell
proliferations in the skin," Dr.
Extensive clinical studies of ZEVALIN have confirmed high response rates and durable responses in patients with relapsed, refractory follicular or transformed B-cell
Thioredoxin is present in egg-secretory products and is a novel B-cell
antigen in schistosome-infected mice.